CeriBell (Nasdaq:CBLL) - Aandelenanalyse
This article provides a stock analysis of CeriBell (Nasdaq:CBLL), a medical technology company specializing in AI-enabled point-of-care EEG solutions. The company's stock is currently trading at US$18.74, with analysts suggesting it is 30.6% undervalued with a target price of US$27. Key developments include FDA clearances for LVO stroke detection, delirium monitoring, and neonatal seizure detection, alongside raised revenue guidance for 2026. However, the company remains unprofitable and has seen significant insider selling.
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference
Ceribell, Inc. announced that its CEO and Co-founder, Jane Chao, Ph.D., will present at the William Blair 46th Annual Growth Stock Conference on June 3, 2026. The presentation will details on the company's focus on transforming the diagnosis and management of patients with serious neurological conditions. A live and archived webcast will be available on Ceribell's investor relations website.
Earnings call transcript: Ceribell Inc. Q1 2026 misses EPS, revenue up
Ceribell Inc. reported a wider-than-expected Q1 2026 EPS loss of $0.52, missing the forecasted $0.36, despite a strong 29% year-over-year revenue increase to $26.5 million. The company attributed the increased net loss to higher operating expenses driven by sales, marketing investments, and litigation costs. Ceribell raised its full-year 2026 revenue guidance to $112-$116 million and emphasized strategic investments in new products like neonate, pediatric, and delirium monitoring solutions, and continued account expansion.
TD Cowen Maintains Ceribell(CBLL.US) With Buy Rating, Maintains Target Price $29
TD Cowen has reiterated its Buy rating for Ceribell (CBLL.US) and maintained its price target of $29. This indicates continued confidence from the analyst firm in the company's prospects.
Ceribell’s Earnings Call Signals Growth Over Profits
Ceribell's latest earnings call revealed robust Q1 2026 revenue growth of 29% and increased hospital adoption, leading to an upgraded full-year revenue guidance of $112 million to $116 million. However, the company acknowledged rising operating expenses, significant litigation costs, and continued negative adjusted EBITDA, indicating a focus on aggressive growth and market expansion over immediate profitability. Despite these losses, Ceribell maintains healthy cash reserves to fund its strategic initiatives and expects future contributions from new offerings like neonate, pediatric, and delirium solutions to drive long-term growth.
CeriBell (CBLL) Q1 Loss Widens Challenging Bullish Growth Narratives
CeriBell (CBLL) reported a wider Q1 2026 loss of US$0.52 EPS, despite quarterly revenue increasing to US$26.5 million. The company's trailing twelve-month revenue reached US$95.1 million, but TTM net loss expanded to US$60.4 million, with losses growing faster than revenue. Investors are weighing strong forecast revenue growth against ongoing losses, a premium P/S multiple of 6.7x, and recent insider selling, while analysts project a potential 60.3% upside.
Ceribell anticipates $112M-$116M 2026 revenue while targeting delirium NTAP of up to $2,171 per patient
Ceribell provided an overview of its financial projections and strategic goals, anticipating revenues between $112 million and $116 million by 2026. A key part of their strategy involves securing a New Technology Add-on Payment (NTAP) for delirium, which could provide up to $2,171 per patient. This financial and strategic outlook was shared during a conference call, highlighting the company's focus on revenue growth and market access for its technologies.
CeriBell Q1 Earnings Call Highlights
CeriBell reported a strong first quarter with a 29% revenue increase, reaching $26.5 million, driven by higher usage of its seizure monitoring system and a significant number of new hospital additions. The company raised its full-year 2026 revenue guidance to $112 million to $116 million and initiated commercial launches for its pediatric/neonatal products and a delirium monitoring solution. Despite increased operating expenses and a wider net loss due to intellectual property litigation, CeriBell remains focused on expanding its market presence and achieving cash flow breakeven.
Ceribell, Inc. (CBLL) reports Q1 loss, beats revenue estimates
Ceribell, Inc. (CBLL) announced its first-quarter results, reporting a loss per share while exceeding revenue expectations. The company's financial performance in Q1 indicates a mixed outcome with revenue growth despite a net loss. This could suggest operational expenses or investment outweighing current income.
CeriBell (CBLL) Q1 2026 Earnings Transcript
CeriBell (CBLL) reported strong Q1 2026 results with a 29% year-over-year revenue growth, driven by record headband utilization and new hospital account additions. The company initiated commercial launches for neonate and pediatric seizure monitoring products and activated pilot sites for delirium monitoring, a new $1 billion market opportunity. Despite increased operating expenses due to sales, marketing, R&D, and significant IP litigation costs, CeriBell raised its full-year revenue guidance and maintains confidence in its market penetration and product pipeline expansion, particularly with a new CMS proposed rule supporting reimbursement for delirium monitoring.
CeriBell Q1 Loss Widens, Revenue Rises; Lifts Full-Year Revenue Guidance
CeriBell reported a wider net loss for Q1 but saw a significant increase in revenue, which prompted the company to raise its full-year revenue outlook. Despite the increased loss, the growth in revenue suggests a positive trajectory for the company's financial performance moving forward. This update indicates CeriBell's confidence in continued sales growth for the remainder of the year.
Ceribell Reports First Quarter 2026 Financial Results
Ceribell, Inc. reported strong first-quarter 2026 financial results, with total revenue increasing 29% to $26.5 million. The company also announced the commercial launch of its neonate and pediatric products and raised its full-year 2026 revenue guidance to $112 million to $116 million. Despite increased operating expenses due to investments and legal costs, the company ended the quarter with $141.2 million in cash, cash equivalents, and marketable securities.
Ceribell Reports First Quarter 2026 Financial Results
Ceribell, Inc. reported strong first-quarter 2026 financial results, with total revenue increasing 29% to $26.5 million compared to the prior year. The company also announced the commercial launch of its neonate and pediatric products and raised its full-year 2026 revenue guidance to between $112 million and $116 million. Despite a net loss of $19.7 million, Ceribell highlighted progress in market adoption and continued investment in innovation.
Number of shareholders of CeriBell, Inc. – NASDAQ:CBLL
This article provides details on the number of shareholders for CeriBell, Inc. (NASDAQ:CBLL). It highlights basic financial information and links to various data providers involved in presenting the company's market data. The article itself does not present specific shareholder numbers but focuses on the topic and where relevant information might be found within the TradingView platform.
[144] Ceribell, Inc. SEC Filing
This article reports on a Form 144 SEC filing by Ceribell, Inc. (CBLL) on May 8, 2026, at 10:09 AM. The filing status is neutral in sentiment and relates to the proposed sale of securities under Rule 144. The document details the filer information, issuer details, and information about the securities to be sold, including their acquisition through restricted stock vesting.
Ceribell CEO Chao Xingjuan sells $783,973 in stock
Ceribell CEO Chao Xingjuan sold $783,973 worth of company stock on May 5, 2026, through a Rule 10b5-1 trading plan, disposing of 39,000 shares at prices between $20.09 and $20.12. Prior to this, Ms. Xingjuan acquired 25,000 shares via stock options for $117,500. Following these transactions, she directly holds 836,347 shares and indirectly holds 369,088 shares through a trust.
Ceribell (NASDAQ: CBLL) CEO sells 39,000 shares after options exercise
Ceribell, Inc. CEO Xingjuan Chao exercised stock options for 25,000 shares at $4.70 and subsequently sold 39,000 shares of common stock at prices ranging from $19.77 to $20.48 per share. These transactions, executed on May 5, 2026, were part of a pre-arranged Rule 10b5-1 trading plan. Following the sales, she directly holds 836,347 shares and indirectly holds 369,088 shares through a trust.
Ceribell CEO Chao Xingjuan sells $783,973 in stock
Ceribell CEO Chao Xingjuan sold $783,973 worth of company stock through a Rule 10b5-1 trading plan on May 5, 2026. This sale involved 39,000 shares at prices between $20.09 and $20.12, following an acquisition of 25,000 shares via stock options for $117,500. The transactions occurred amidst a 68% stock surge and an InvestingPro analysis indicating the stock is overvalued.
FMR LLC holds 4.85M CERIBELL shares (CBLL) — Amendment No.3
FMR LLC has filed an Amendment No. 3 to a Schedule 13G/A, disclosing beneficial ownership of 4,850,430.52 shares, or 12.9%, of Ceribell Inc.'s (CBLL) common stock. The filing indicates FMR LLC has sole voting power over 4,845,632 shares and sole dispositive power over all 4,850,430.52 shares. This report highlights a significant passive stake held by FMR LLC in Ceribell.
CeriBell (Nasdaq:CBLL) - Stock Analysis
This Simply Wall St analysis provides an in-depth look at CeriBell (Nasdaq:CBLL), a medical technology company specializing in AI-powered EEG solutions. The report covers financial performance, growth forecasts, risk analysis, recent insider transactions, and FDA clearances for new medical devices, including an LVO stroke detection monitor and a delirium monitoring solution. Despite being unprofitable, analysts predict revenue growth and a stock price increase, with the company aiming to address unmet needs in acute care settings.
Insider sells 78,000 CBLL shares and 2,084 more (CBLL)
Xingjuan Chao, an insider, reported Rule 144 sales of Ceribell, Inc. (CBLL) common stock through SEC Form 144. The filing details multiple sales transactions totaling 78,084 shares across February, March, and April 2026, with proceeds exceeding $1.4 million. The report also lists securities to be sold, including 39,000 shares associated with Fidelity Brokerage Services LLC, and mentions prior option-related exercises.
Ceribell CTO Raymond Woo sells $226,928 of CBLL common stock By Investing.com
Raymond Woo, CTO of Ceribell, Inc. (NASDAQ:CBLL), sold 11,104 shares of common stock totaling $226,928 on May 1, 2026. The sales, executed under a pre-arranged trading plan, followed the exercise of stock options. This comes as Ceribell shares have surged 86% in six months, though InvestingPro analysis suggests the stock is currently overvalued.
Ceribell CTO Raymond Woo sells $226,928 of CBLL common stock
Ceribell's Chief Technology Officer, Raymond Woo, sold 11,104 shares of common stock worth $226,928 on May 1, 2026. These transactions, conducted under a pre-arranged Rule 10b5-1 trading plan, followed the exercise of stock options. The sale occurred as Ceribell shares experienced an 86% surge, but an InvestingPro analysis suggests the stock is overvalued.
Ceribell (NASDAQ: CBLL) CTO sells shares under 10b5-1 trading plan
Ceribell, Inc.'s Chief Technology Officer, Raymond Woo, executed an exercise-and-sell transaction involving 11,104 shares of company common stock. Woo exercised stock options at $4.70 and $2.24 per share and subsequently sold the same number of shares in open-market transactions at an average price of approximately $20.40 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Woo directly holds 197,648 shares of Ceribell common stock.
Ceribell to Participate in the Bank of America Securities 2026 Health Care Conference
Ceribell, a brain health technology company, announced its participation in the Bank of America Securities 2026 Health Care Conference. Dr. Jane Seaman, President and CEO, will present at the conference, highlighting the company's advancements in neurological diagnostics. This signifies Ceribell's continued engagement with the financial community and its commitment to showcasing its innovative solutions.
CBLL (CBLL) Form 144 shows option-based sales and recent insider disposals
Ceribell, Inc. (CBLL) has filed a Form 144 disclosing proposed sales of common stock related to option grants, with planned sales totaling 1,469 and 9,635 shares, both scheduled for May 1, 2026. The filing also revealed four recent open-market sales by Raymond Woo, occurring between February and April 2026, with an aggregate of 33,041 shares sold for over $650,000. These transactions are detailed with specific share counts, dates, and cash proceeds.
CeriBell (NASDAQ:CBLL) Stock Price Down 8.1% - Should You Sell?
CeriBell (NASDAQ:CBLL) shares experienced an 8.1% drop, trading at $19.105 with reduced volume. Despite analyst consensus for a "Moderate Buy" and recent beats on EPS and revenue, the company remains unprofitable with a negative net margin. Insider selling of over $2.41 million in the last three months also raises concerns for investors.
CeriBell, Inc. (NASDAQ:CBLL) Sees Significant Decrease in Short Interest
CeriBell, Inc. (NASDAQ:CBLL) experienced a significant decrease in short interest in April, falling by 18.6% to 1,530,162 shares. Insider selling by CTO Raymond Woo and VP David Foehr was noted, yet institutional investment reportedly increased, with JPMorgan Chase & Co. significantly raising its stake. The company's stock traded up on Thursday, and analysts have a "Moderate Buy" consensus rating with a target price of $23.20.
Ceribell to Participate in the Bank of America Securities 2026 Health Care Conference
Ceribell, a company focused on neurological monitoring, announced its participation in the Bank of America Securities 2026 Health Care Conference. They will present at the event and host one-on-one meetings, indicating their active engagement with the financial community. This participation highlights their efforts to communicate their progress and strategy to investors.
Ceribell to Participate in the Bank of America Securities 2026 Health Care Conference
Ceribell, a medical technology company, announced that its CEO, Jane Chao, Ph.D., and CFO, Scott Blumberg, will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on May 13, 2026. The company focuses on diagnosing and managing neurological conditions with its FDA-cleared Ceribell System, a portable EEG platform. A live and archived webcast of their presentation will be available on Ceribell's investor relations website.
Ceribell CEO, CFO to speak at Bank of America health conference
Ceribell (Nasdaq: CBLL) announced that its CEO, Jane Chao, and CFO, Scott Blumberg, will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on May 13, 2026. The presentation is scheduled for 3:40 p.m. PST / 6:40 p.m. EST. A live and archived webcast of the event will be available on the company's Investor Relations website.
Ceribell to Participate in the Bank of America Securities 2026 Health Care Conference
Ceribell, a medical technology company specializing in neurological conditions, announced that its CEO and CFO will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on May 13, 2026. The event will be webcast live and archived on the company's investor relations website. Ceribell focuses on developing advanced EEG platforms for rapid diagnosis and continuous monitoring in acute care settings.
CeriBell, Inc. - Common Stock (Nasdaq:CBLL) Stock Quote
This article provides a stock quote for CeriBell, Inc. (CBLL) on Nasdaq, showing its current price, daily performance, volume, and trading ranges. It also lists recent news and financial announcements from the company, including upcoming earnings reports and participation in healthcare conferences, highlighting key developments like FDA designations for new solutions.
CBLL Price Today: CeriBell, Inc. Stock Price, Quote & Chart | MEXC
CeriBell, Inc. (CBLL) is trading at $21.21, reflecting a 0.71% increase from its previous close, with a market capitalization of $798.18M. The medical technology company, which specializes in point-of-care EEG systems for neurological conditions, has shown strong performance with a 19.40% return over the past month and 30.98% over the last year. Investors can buy and trade CBLL on MEXC through a simple three-step process involving account creation, fund deposit, and trade execution.
CeriBell, Inc. (NASDAQ:CBLL) Given Average Recommendation of "Moderate Buy" by Brokerages
CeriBell, Inc. (NASDAQ:CBLL) has received a "Moderate Buy" consensus rating from six brokerages, with an average 12-month price target of $23.20. Despite recent insider selling by the CEO and CTO, the company's latest quarterly earnings exceeded estimates, though it remains unprofitable. CeriBell specializes in newborn hearing screening devices and its stock has experienced significant institutional investor activity.
Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026
Ceribell, Inc. (Nasdaq: CBLL) announced it will release its first-quarter 2026 financial results after trading closes on Monday, May 11, 2026. Following the release, the company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results, with a live webcast available on their investor relations website. Ceribell is a medical technology company specializing in an AI-powered EEG system for neurological condition diagnosis and monitoring.
[ARS] Ceribell, Inc. SEC Filing
This article announces an ARS SEC filing by Ceribell, Inc. (CBLL) on April 20, 2026. The filing has a low impact and neutral sentiment, indicating it's a routine annual report. It also provides an overview of Ceribell Inc.'s stock data, recent news, and other SEC filings.
Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026
Ceribell, Inc. (Nasdaq: CBLL) announced it will release its first quarter 2026 financial results after market close on Monday, May 11, 2026. The company will host a conference call on the same day at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Investors can access the call via phone or webcast through Ceribell's investor relations website.
Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026
Ceribell, Inc. announced it will release its first-quarter 2026 financial results after market close on Monday, May 11, 2026. The company will host a conference call on the same day at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Interested parties can access the call via phone or a webcast on Ceribell's investor relations website.
Ceribell sets May 11 investor call for first-quarter results
Ceribell (Nasdaq: CBLL) announced it will release its first quarter 2026 financial results after market close on Monday, May 11, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results, which investors can access via phone or webcast. The announcement follows Ceribell's Q4 and full-year 2025 report, which showed strong revenue growth and gross margins, alongside rising operating expenses.
Ceribell, Inc. unveils AI-powered EEG platform for neurologists at AAN2026
Ceribell, Inc. is launching an AI-powered point-of-care EEG system for neurologists at AAN2026, showcasing it in their new Innovation Studio. This initiative aims to enhance seizure monitoring through collaborative development with clinical experts, reflecting Ceribell's ongoing efforts to advance neurological diagnostic tools and clinician training.
Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026
Ceribell, Inc. (Nasdaq: CBLL) announced it will release its first quarter 2026 financial results on Monday, May 11, 2026, after the close of trading. The medical technology company will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results. Ceribell specializes in developing the Ceribell System, an FDA-cleared, point-of-care EEG platform for diagnosing and managing neurological conditions.
Ceribell to Report First Quarter 2026 Financial Results on May 11, 2026
Ceribell, Inc. announced it will release its first-quarter 2026 financial results on Monday, May 11, 2026, after the close of trading. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. Ceribell is a medical technology company specializing in point-of-care EEG platforms for diagnosing and managing neurological conditions.
Rapid point-of-care EEG gives clinicians real-time diagnosis options, Ceribell, Inc. argues
Ceribell, Inc. emphasizes the crucial role of rapid point-of-care EEG in detecting non-convulsive seizures, particularly in comatose patients, which are often missed due to subtle symptoms. The company advocates for bedside EEG technology to provide immediate neurodiagnostic insights, leading to faster intervention and improved patient outcomes. Ceribell highlights its commitment through webinars promoting EEG use in critical care and recognizing staff contributions to training initiatives.
Ceribell, Inc. promotes point of care EEG for adherence to ACNS neonatal seizure guidelines
Ceribell, Inc. is advocating for the adoption of its point-of-care EEG technology to help healthcare providers comply with the 2025 ACNS guidelines for continuous EEG monitoring in neonates. The company emphasizes the high prevalence and frequent undetected nature of seizures in critically ill newborns, highlighting their device's role in improving detection accuracy. This push aligns with Ceribell's prior efforts to innovate in neonatal care, including recognizing key individuals for their contributions to monitoring solutions and staff development.
Ceribell, Inc. webinar promotes point of care EEG use in critical care
Ceribell, Inc. is promoting the use of point-of-care EEG (POCEEG) in critical care through a new webinar. This initiative addresses the diagnostic challenges of seizures in patients with altered mental status by showcasing "Clarity," their rapid EEG platform. The company aims to minimize diagnostic uncertainty and improve patient outcomes in emergency and ICU settings.
Ceribell: Chao Xingjuan sells $717k in shares
Chao Xingjuan, President and CEO of Ceribell, sold 39,000 shares of the company's common stock for $717,600 on April 6, 2026. This transaction followed a 46% surge in the medical device company's stock over the past six months, although InvestingPro analysis indicates it may be overvalued. Concurrently, Chao exercised options to acquire 25,000 shares for $117,500, and still directly holds over 850,000 shares of Ceribell.
Ceribell: Chao Xingjuan sells $717k in shares By Investing.com
Chao Xingjuan, President and CEO of Ceribell, Inc., sold 39,000 shares of common stock for a total of $717,600 on April 6, 2026. These sales were executed under a pre-arranged Rule 10b5-1 trading plan at an average price of $18.4, even as the company's stock has seen a 46% surge in the last six months. On the same day, Chao also exercised options to acquire 25,000 shares, and retains significant direct and indirect ownership in the company.
Ceribell (CBLL) CEO trades 39K shares under 10b5-1 plan
Ceribell CEO Xingjuan Chao exercised stock options for 25,000 shares at $4.70 and sold 39,000 shares at a weighted average price of $18.40, a total of $717,600. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. After the trades, Chao directly holds 850,347 shares and indirectly holds 369,088 shares through a trust, indicating the sales were for routine liquidity and compensation rather than a significant change in ownership stance.
Ceribell: Chao Xingjuan sells $717k in shares
Ceribell's President and CEO, Chao Xingjuan, sold 39,000 shares of common stock for $717,600 on April 6, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, with shares sold at an average price of $18.4, despite the stock's 46% surge over six months. Concurrently, Chao exercised options to acquire 25,000 shares for $117,500 and now directly owns 850,347 shares, with additional indirect ownership.
